Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

• Status: Terminated
• Trial end date: 2007-11-07
• Target enrollment: 0
• Participant gender: All

Summary

This research is to test the effectiveness and toxicity of both Ifosfamide and Doxorubicin. It also aims to explore the relationship between EBV DNA and clinical response in patients with advanced naso-pharyngeal cancer which has been previously treated with chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Treatments: Doxorubicin; Ifosfamide; Isophosphamide mustard; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Histological diagnosis of NPC

• Age > 18 years old

• Measurable metastatic or recurrent disease (s)

• Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry.

• ECOG PS 0, 1 or 2

• WBC > 3,500/uL and ANC > 1,500/uL Platelet > 100,000/uL Creatinine - within normal limits SGOT < 3 X UNL Bilirubin < 2.0 mg/dL

• Ejection fraction > 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status.

• Random blood glucose level < 250 mg

• Signed informed consent

Exclusion Criteria:

• Received more than one prior chemotherapy for metastatic or recurrent disease

• Ejection fraction < 45%

• WBC < 3,500/UL or ANC < 1,500/UL or P/t < 100,000/UL or SCOT> 3 x UNL or Bilirubin > 2.0 mg/dL or Creatinine > UNL

• ECOG PS > 3

• Hx of myocardial infarction within last 6 months

• Random blood glucose level less than or equal 250 mg